

Curriculum Vitae

Jin-Hyeok Hwang, M.D., Ph.D. (Last updated: 2023-02-10)

Education and Training

2003-2005	Ph.D., in Internal Medicine, Seoul National University, Seoul, Korea
2001-2003	M.S., in Internal Medicine, Seoul National University, Seoul, Korea
1987-1993	B.S., in Medicine, Seoul National University, Seoul, Korea
2007-2009	Visiting Scholar, Medical Oncology Branch, Center for Cancer Research, NCI/NIH, Bethesda, MD, USA.
2001-2003	Fellowship in Internal Medicine, Division of Gastroenterology, Seoul National University Hospital, Seoul, Korea
1994-1998	Residency in Internal Medicine, Seoul National University Hospital, Seoul, Korea
1993-1994	Internship in Medicine, Seoul National University Hospital, Seoul, Korea

Professional Experiences

2014-present	Professor, Department of Internal Medicine Seoul National University College of Medicine/Seoul National University Bundang Hospital
2014-present	Director, Health Promotion Center, Seoul National University Bundang Hospital
2009-2014	Associate Professor, Department of Internal Medicine Seoul National University College of Medicine/Seoul National University Bundang Hospital
2005-2009	Assistant Professor, Department of Internal Medicine Seoul National University College of Medicine/Seoul National University Bundang Hospital

Present interests

- Liquid biopsy (ctDNA and CTC) based MRD detection and monitoring in PC/BTCs (WGS/ddPCR)
- Early diagnosis of pancreatic cancer and bile duct cancer (epigenome/proteome/metabolome/PCR-based)
- Cancer evolution and molecular subtyping using WGS/WES/WTS
- Establishment of national cancer registry and cancer biobank
- Reprogramming of tumor microenvironment using multi-OMICS (scRNA-seq/gut and tissue microbiome)

Pancreatic cancer (PC), biliary tract cancer (BTCs)

Recent publications as a corresponding author (2019-current)

Shin DW, Lee JC, Kim J, Woo SM, Lee WJ, Han SS, Park SJ, Choi KS, Cha HS, Yoon YS, Han HS, Hong EK, **Hwang JH**. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. *Eur J Surg Oncol* 2019;45:2159-2165

Kim JH, Youn Y, Kim KT, Jang G, **Hwang JH**. Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cells. *Sci Rep*. 2019;9:17889

Lee YS, Lee J, Lee JC, Yang SY, Kim J, **Hwang JH**. Neoadjuvant therapy versus upfront surgery in resectable pancreatic

cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. *Sci Rep* 2019;9:15662

Lee JC, Woo SM, Shin DW, Kim J, Yang SY, Kim MJ, Kim JW, Kim JW, Lee WJ, Cha HS, Park P, Kim J, **Hwang JH**. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. *Am J Clin Oncol* 2020;43:654-659

Chung KH, Lee JC, Lee J, Cho IK, Kim J, Jang W, Yoo BC, **Hwang JH**. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. *Pancreatol* 2020;20:1465-1471

Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, **Hwang JH**. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. *Gut Liver* 2020;14:521-528

Ahn S, Lee JC, Shin DW, Kim J, **Hwang JH**. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. *Sci Rep* 2020;10:12348

Shin DW, Kim MJ, Lee JC, Kim J, Woo SM, Lee WJ, Lee KH, **Hwang JH**. Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study. *Am J Clin Oncol* 2020;43(6):422-427.

Lee JC, Shin DW, Park H, Kim J, Youn Y, Kim JH, Kim J, **Hwang JH**. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase I trial. *Gastrointest Endosc* 2020;92:1044-1052

Kim JH, Youn Y, Lee JC, Kim J, **Hwang JH**. Involvement of the NF- κ B signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. *J Cancer* 2020;11:5601-5611

Lee J, Lee JC, Kim HW, Kim J, **Hwang JH**. Post-operative Muscle Mass Restoration as a Prognostic Factor in Resected Pancreatic Cancer Patients. *PLoS ONE* 2020;15:E0238649

Jung JH, Shin DW, Kim J, Lee JC, **Hwang JH**. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. *Cancers (Basel)* 2020;12:E3137

Shin DW, Lee JC, Kim J, Yoon YS, Han HS, Kim H, **Hwang JH**. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. *Pancreatol* 2021;21:796-804.

Shin DW, Kim MA, Lee JC, Kim J, **Hwang JH**. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. *BMC Res Notes* 2021;14:272

Lee YS, Lee JC, Kim JH, Kim J, **Hwang JH**. Pharmacoefficacy of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. *Sci Rep* 2021;11:20152

Ahn S, Lee JC, Kim J, Kim YH, Yoon YS, Han HS, Kim H, **Hwang JH**. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy. *Gut Liver*. 2022;16:129-137

Shin DW, Park J, Lee JC, Kim J, Kim YH, **Hwang JH**. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. *Cancers (Basel)*. 2022;14:2476

Kim JH, Youn Y, Lee JC, Kim J, Ryu JK, **Hwang JH**. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. *Cancer Biomark*. 2022

Jung K, Park J, Jong JH, Lee JH, Kim J, **Hwang JH**. Real-world outcomes of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy regimen in advanced biliary tract cancer: A propensity score-matched analysis. *Gut Liver*. 2022

Kim jh, Youn Y, Hwang JH. NCAPH Stabilizes GEN1 in Chromatin to Resolve Ultra-Fine DNA Bridges and Maintain Chromosome Stability. *Mol Cells*. 2022

Lee H, Kim SY, Kim DW, Park YS, **Hwang JH**, Cho S, Cho JY. Serum protein profiling of lung, pancreatic, and colorectal cancers reveals alcohol consumption-mediated disruptions in early-stage cancer detection. *Heliyon*. 2022

Jung JH, Song C, Jung IH, Ahn J, Kim B, Jung K, Lee JC, Kim J, **Hwang JH**. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. *Front Oncol*. 2022

Lee JC, Lee BJ, Park C, Song H, Ock CY, Sung H, Woo S, Youn Y, Jung K, Jung JH, Ahn J, Kim B, Kim J, Seo J, **Hwang JH**. Efficacy improvement in searching MEDLINE database using a novel PubMed visual analytic system: EEEvis. *PLoS One*.